Navigation Links
Rigel to Present at JP Morgan Healthcare Conference
Date:1/6/2011

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13th at 11:30 a.m. PST.

(Logo:  http://photos.prnewswire.com/prnh/20030226/RIGLLOGO)

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral syk inhibitor that has started its phase 3 clinical trial program for RA, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.Contact: Ryan MaynardPhone: 650.624.1284Email: invrel@rigel.com
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Rigel Announces Third Quarter 2009 Financial Results
2. Rigel Announces Presentations at Two Investor Conferences
3. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
4. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
5. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
8. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
9. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
10. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
11. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... 2017  Designers of primary cell wearable medical and ... 50% and extend battery life with the MAX20310 ultra-low ... (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... voltage of just 0.7V for new high-energy density battery ... well as the more common Alkaline battery architecture. With ...
(Date:3/29/2017)... 2017 Stryker announced today that it has ... in partnership with Great Place to Work (GPTW). We ... This list highlights the top U.S. companies with 1,000 ... also demonstrating respect, compassion and concern for their employees, ... determine the companies on the list, GPTW asked more ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has ... of more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers ... and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Full Contact K9, ... of Pet Protect Law that assists dog owners in creating legally-enforceable pet ... owners in taking the natural next step to protect their new companion. Says Evan ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... opportunities for attending prescribers at the upcoming World Congress, in Hollywood Florida April ... always been recognized as the visionary leader in the training of physicians, scientists, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on ... the challenges employers face in trying to balance both short-term and long-term benefits ... Adding to the growing complexity, companies are finding that the short-term strategies ...
Breaking Medicine News(10 mins):